# Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

> **NCT02851589** · PHASE1,PHASE2 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
- Mantle Cell Lymphoma
- B-cell Prolymphocytic Leukemia
- Diffuse Large Cell Lymphoma

## Interventions

- **BIOLOGICAL:** PCAR-019 (anti-CD19 CAR-T cells)

## Key facts

- **NCT ID:** NCT02851589
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2018-11
- **Final completion:** 2019-11
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2016-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02851589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02851589, "Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02851589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*